Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(2), С. 554 - 554
Опубликована: Янв. 10, 2025
The
treatment
of
Non
Small
Cell
Lung
Cancer
(NSCLC)
has
been
revolutionised
by
the
introduction
targeted
therapies.
With
improvement
response
and
frequently
overall
survival,
however,
a
whole
new
set
adverse
events
emerged.
In
fact,
due
to
peculiar
mechanism
action
each
one
tyrosine
kinase
inhibitors
other
therapies,
every
drug
its
own
specific
safety
profile.
addition,
this
profile
could
not
fully
emerge
from
clinical
trials
data,
as
patients
in
practice
usually
have
more
comorbidities
frailties.
Cardiotoxicity
is
well-known
established
event
anti-cancer
However,
only
recently
it
become
central
topic
for
therapies
NSCLC,
unknown
real
range
frequency.
Management
toxicity
begins
with
prevention,
must
balance
need
continuing
an
effective
anticancer
versus
low
risk
even
fatal
preservation
long-term
quality
life.
aim
review
summarise
current
knowledge
focusing
on
currently
used
NSCLC.
Язык: Английский
Tyrosine kinase inhibitors induce cardiotoxicity by causing Ca2+ overload through the inhibition of phosphoinositide 3-kinase activity
Biochemical and Biophysical Research Communications,
Год журнала:
2025,
Номер
771, С. 152027 - 152027
Опубликована: Май 15, 2025
Язык: Английский
Serum creatine kinase elevation following tyrosine kinase inhibitor treatment in cancer patients: Symptoms, mechanism, and clinical management
Clinical and Translational Science,
Год журнала:
2024,
Номер
17(11)
Опубликована: Окт. 29, 2024
Abstract
Molecular
targeted
tyrosine
kinase
inhibitors
(TKIs)
have
produced
unprecedented
treatment
response
in
cancer
therapy
for
patients
harboring
specific
oncogenic
mutations.
While
the
TKIs
are
mostly
well
tolerated,
they
were
reported
to
increase
serum
levels
of
creatine
(CK)
and
cause
muscle
metabolism‐related
toxicity.
CK
is
an
essential
enzyme
involved
cellular
energy
metabolism
function.
Elevated
can
arise
from
both
physiological
pathological
factors,
as
triggered
by
drug
classes.
The
incidence
elevation
induced
a
few
approved
(brigatinib,
binimetinib,
cobimetinib‐vemurafenib
combination
[Food
Drug
Administration,
United
States];
aumolertinib,
sunvozertinib
[only
National
Medical
Products
China])
over
35%.
elevation‐related
symptoms
include
myopathy,
myositis,
inclusion
body
myositis
(IBM),
cardiotoxicity,
rhabdomyolysis,
rash,
acneiform
dermatitis.
High‐level
or
severe
symptomatic
may
necessitate
dose
reduction
indirectly
dampen
TKI
efficacy.
This
review
presents
updated
summary
about
prevalence
rate
recent
research
mechanisms
leading
TKI‐induced
patients.
utility
monitoring
predicting
adverse
effects
their
management
will
also
be
discussed.
Язык: Английский